Clinical trials: Non Alcoholic Fatty Liver
Dyslipidemia, Diabetes
Meta-analyses of Fructose and Cardiometabolic Risk
Diabetes and heart associations continue to discourage high intakes of dietary fructose, a constituent part of the sucrose molecule that is found in fruits and vegetables as a natural sugar and in some processed foods and…
- Conditions
- Dyslipidemia, Diabetes, Prediabetes, Dysglycemia
- Trial name
- NCT01363791
- Testing
- Dietary fructose
- Where
- Canada
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- John Sievenpiper
Safety and Tolerability
A First in Human Study to Evaluate the Safety, Tolerability and PK of GB1211 in Healthy Subjects
This was a Phase 1, randomized, double-blind, placebo-controlled, first-in-human study in which the safety, tolerability, and pharmacokinetics of orally administered GB1211 will be evaluated in healthy adult subjects and adult…
- Trial name
- NCT03809052
- Testing
- GB1211
- Where
- United Kingdom
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Galecto Biotech AB
Non-alcoholic Fatty Liver Disease
Prospective Cohort Study in Patients With NAFLD
To assess the importance of intracellular signalling pathways and its deregulation in adiposity and diabetes-related insulin resistance, liver tissue samples of patients suffering from non-alcoholic fatty liver disease (NAFLD)…
- Trial name
- NCT00575133
- Where
- Switzerland
- Volunteers
- 150 people
- Sponsor
- University of Zurich
Fatty Liver, NAFLD - Non-Alcoholic Fatty Liver Disease
Detecting Liver Fibrosis in Patients At-risk
The project will establish a research cohort (called STELIR; STEatotisk Liver-risk In Rogaland) based on a biobank with an associated health register.
- Conditions
- Fatty Liver, NAFLD - Non-Alcoholic Fatty Liver Disease, Nash, MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease)
- Trial name
- STELIR (NCT07775638)
- Testing
- Routine study procedure
- Where
- Norway
- Volunteers
- 1,200 people
- Sponsor
- Helse Stavanger HF
NAFLD, TYPE 2 DIABETES
Resveratrol for the Treatment of Non Alcoholic Fatty Liver Disease and Insulin Resistance in Overweight Adolescents
The current project is designed as a 30-day pilot trial to demonstrate the safety and tolerability of resveratrol therapy in overweight adolescents to decrease liver fat, and improve insulin sensitivity to prevent type 2 diabetes.
- Conditions
- NAFLD, TYPE 2 DIABETES, METABOLIC SYNDROME
- Trial name
- NCT02216552
- Testing
- Resveratrol
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- University of Manitoba
Food Insecurity
Implementing Food Referrals for Equity and Sustained Health
Food insecurity (FI) disproportionately affects those who have been historically marginalized and significantly contributes to poor health outcomes.
- Trial name
- I-FRESH (NCT06661538)
- Testing
- Food Security Screening & Referral Program
- Where
- 2 sites in United States
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- University of California, San Diego
Non-alcoholic Fatty Liver Disease
Effect of Fructose Reduction on Non-alcoholic Fatty Liver Disease (NAFLD) and Metabolic Syndrome in Overweight Children
The aim of the present study is to find out if a dietary intervention mainly focusing on fructose reduction has a preventive effect on the development and progression of NAFLD and the metabolic syndrome in overweight children.
- Trial name
- NCT01306396
- Testing
- dietary intervention mainly focusing on fructose reduction
- Where
- Germany
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University of Hohenheim
NAFLD, NASH With Fibrosis
Dasatinib and Quercetin to Treat Fibrotic Non-alcoholic Fatty Liver Disease
To examine the effect of dasatinib plus quercetin on liver fibrosis in individuals with biopsy proven NAFLD with fibrosis by performing a double-blind randomized controlled proof-of-principle study
- Conditions
- NAFLD, NASH With Fibrosis, Liver Fibrosis
- Trial name
- NCT05506488
- Testing
- Dasatinib 100 MG + Quercetin (1000 MG)
- Where
- Netherlands
- Volunteers
- 30 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Nonalcoholic Fatty Liver Disease (NAFLD), Nonalcoholic Steatohepatitis (NASH)
Quantitative Ultrasound Techniques for Diagnosis of Nonalcoholic Steatohepatitis
Nonalcoholic fatty liver disease is the most common liver disease in Western countries, due in large part to its association with type 2 diabetes and obesity.
- Trial name
- QUS in NASH (NCT03572465)
- Testing
- Acoustic radiation force impulse (ARFI), magnetic resonance elastography (MRE)
- Where
- Canada
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Nonalcoholic Steatohepatitis
Efficacy and Safety of Viusid in Patients With Nonalcoholic Steatohepatitis
The purpose of the study is to evaluate whether Viusid, a nutritional supplement, in combination with diet and exercise improve the histological results (steatosis, necro-inflammatory activity and fibrosis) in comparison with…
- Trial name
- NCT00509418
- Testing
- Viusid, Hypocaloric Diet with controlled exercise
- Where
- Cuba
- Volunteers
- 60 people
- Sponsor
- Catalysis SL
Nonalcoholic Steatohepatitis, Fatty Liver Disease
Bovine Colostrum for Patients With Non Alcoholic Fatty Liver Disease
Trial Synopsis: Bovine Colostrum for patients with non alcoholic fatty liver disease (NAFLD). Design: This is a single-arm, open-label, before-and after exploratory trial of 30 days of Bovine Colostrum Powder (BCP) to improve…
- Trial name
- NCT01016418
- Testing
- Bovine colostrum powder
- Where
- Israel
- Volunteers
- 30 people
- Sponsor
- Hadassah Medical Organization
NASH (Nonalcoholic Steatohepatitis), NAFLD (Nonalcoholic Fatty Liver Disease)
Effects of ACC Inhibitor on Lipid and Lipoprotein Metabolism
The purpose of this study is to assess the effects of an investigational drug, PF-05221304 (PF'1304) on the way the liver handles fat.
- Trial name
- NCT04395950
- Testing
- PF-05221304
- Sponsor
- Columbia University
Non-Alcoholic Fatty Liver Disease, Hyperuricemia
Assocaiton Between Uric Acid Trajecteries and Remission of NAFLD in NAFLD Individuals
Uric acid is the end product of dietary or endogenous purines degradation, and hyperuricemia is one of the most common metabolic disorders.
- Trial name
- NCT05245890
- Volunteers
- 2,000 people
- Sponsor
- Ningbo No. 1 Hospital
Non-Alcoholic Fatty Liver Disease (NAFLD), Nonalcoholic Steatohepatitis (NASH)
Evaluation of Multi-Organ Metabolism and Perfusion in NAFLD by Total Body Dynamic PET Scan on EXPLORER
Evaluation of Multi-Organ Metabolism and Perfusion in Non-Alcoholic Fatty Liver Disease (NAFLD) by Total Body Dynamic PET Scan on EXPLORER
- Trial name
- EXPLORER (NCT04165343)
- Testing
- Positron Emission Tomography (PET) on EXPLORER, Magnetic Resonance Imaging, Echocardiogram and Electrocardiogram
- Where
- United States
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- University of California, Davis
Nonalcoholic Fatty Liver Disease (NAFLD)
Postprandial Lipotoxicity and Nonalcoholic Fatty Liver Disease
Nonalcoholic fatty liver disease (NAFLD) is mainly considered a nutrition-related disease and life-style/diet interventions showed some promising results.
- Trial name
- LITONAS (NCT03836443)
- Testing
- western diet" meal
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Obesity, Morbid Obesity
Effectiveness and Tolerability of Phentermine in Patients Under Bariatric Surgery
Surgical management of Morbid Obesity is increasingly frequent. A low-calorie diet is recommended with the main goal of reducing intrahepatic fat infiltration, fat tissue and making easier the surgery.
- Conditions
- Obesity, Morbid Obesity, Bariatric Surgery, Non-alcoholic Fatty Liver
- Trial name
- NCT03849729
- Testing
- Phentermine
- Where
- Mexico
- Volunteers
- 92 people
- Sponsor
- Hospital Juarez de Mexico
Liver Steatoses
Subclinical Cardiovascular Changes in NAFLD Patient (Predictive Value of Speckle Tracking Echocardiography )
the goal of this study (observational study ) is to learn about the subclinical cardiovascular changes in patients with nonalcoholic fatty liver . the main questions it aims to answer are 1.
- Trial name
- NCT05790057
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Assiut University
Non-alcoholic Steatohepatitis (NASH)
A Study to Test Safety and Efficacy of Survodutide (BI456906) in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3)
This study is open for men and women with a liver disease called nonalcoholic steatohepatitis (NASH) and liver fibrosis. The purpose of the study is to find out whether a medicine called BI 456906 helps patients with NASH and…
- Trial name
- NCT04771273
- Testing
- Survodutide
- Where
- 154 sites in United States, Australia and 23 more
- Volunteers
- 295 people
- Sponsor
- Boehringer Ingelheim
Non-Alcoholic Fatty Liver Disease
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BAR 502 in Healthy Subjects
This is a prospective, single-center, randomized, double-blind, placebo-controlled, single-ascending dose (SAD) phase 1 study to evaluate the safety and tolerability of single-ascending doses of BAR 502 in healthy male and female…
- Trial name
- NCT05203367
- Testing
- BAR502
- Where
- Portugal
- Volunteers
- healthy volunteers welcome
- Sponsor
- BAR Pharmaceuticals s.r.l.
Adolescent Obesity, Hypertension,Essential
Treatment and Handling Severe Obesity-Related Comorbidities in Adolescents Through Exercise
The main objective of this project is to analyze the effect of a tailor-made, one-to-one, exercise program (aiming to treat and handle obesity-related comorbidities in adolescents with severe obesity at high risk of…
- Conditions
- Adolescent Obesity, Hypertension,Essential, Non-Alcoholic Fatty Liver Disease, Dyslipidemias
- Trial name
- THOR-X (NCT06520800)
- Testing
- Treatment and handling obesity-related comorbidities in adolescents through exercise
- Volunteers
- 24 people
- Sponsor
- University of Lisbon
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.